Peter Haytko
Overview
Explore the profile of Peter Haytko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moores S, Chiu M, Bushey B, Chevalier K, Luistro L, Dorn K, et al.
Cancer Res
. 2016 May;
76(13):3942-53.
PMID: 27216193
Non-small cell lung cancers (NSCLC) with activating EGFR mutations become resistant to tyrosine kinase inhibitors (TKI), often through second-site mutations in EGFR (T790M) and/or activation of the cMet pathway. We...
2.
Paul S, Connor J, Nesspor T, Haytko P, Boakye K, Chiu M, et al.
Protein Expr Purif
. 2016 Jan;
121:133-40.
PMID: 26826313
Bispecific antibody generation is actively pursued for therapeutic and research antibody development. Although there are multiple strategies for generating bispecific antibodies (bsAbs); the common challenge is to develop a scalable...
3.
Zhang L, McCabe T, Condra J, Ni Y, Peterson L, Wang W, et al.
Int J Biol Sci
. 2012 Feb;
8(3):310-27.
PMID: 22355267
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising therapeutic target for treating coronary heart disease. We report a novel antibody 1B20 that binds to PCSK9 with sub-nanomolar affinity and...
4.
Glantschnig H, Scott K, Hampton R, Wei N, McCracken P, Nantermet P, et al.
J Pharmacol Exp Ther
. 2011 May;
338(2):568-78.
PMID: 21531794
Genetic studies have linked both osteoporotic and high bone mass phenotypes to low-density lipoprotein receptor-related proteins (LRP4, LRP5, and LRP6). LRPs are receptors for inhibitory Dickkopf-1 (DKK1) protein, and treatment...
5.
Ni Y, Di Marco S, Condra J, Peterson L, Wang W, Wang F, et al.
J Lipid Res
. 2010 Oct;
52(1):78-86.
PMID: 20959675
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) regulates LDL cholesterol levels by inhibiting LDL receptor (LDLr)-mediated cellular LDL uptake. We have identified a fragment antigen-binding (Fab) 1D05 which binds PCSK9 with...
6.
Glantschnig H, Hampton R, Lu P, Zhao J, Vitelli S, Huang L, et al.
J Biol Chem
. 2010 Oct;
285(51):40135-47.
PMID: 20929859
Wnt/LRP5 signaling is a central regulatory component of bone formative and resorptive activities, and the pathway inhibitor DKK1 is a suppressor of bone formation and bone mass accrual in mice....
7.
Aste-Amezaga M, Zhang N, Lineberger J, Arnold B, Toner T, Gu M, et al.
PLoS One
. 2010 Feb;
5(2):e9094.
PMID: 20161710
Background: Notch receptors normally play a key role in guiding a variety of cell fate decisions during development and differentiation of metazoan organisms. On the other hand, dysregulation of Notch1...
8.
An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, et al.
MAbs
. 2010 Jan;
1(6):572-9.
PMID: 20073128
The Fc region of an antibody mediates effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and plays a key role in the in vivo half-life of...
9.
Montgomery D, Wang Y, Hrin R, Luftig M, Su B, Miller M, et al.
MAbs
. 2010 Jan;
1(5):462-74.
PMID: 20065653
The human D5 monoclonal antibody binds to the highly conserved hydrophobic pocket on the N-terminal heptad repeat (NHR) trimer of HIV-1 gp41 and exhibits modest yet relatively broad neutralization activity....
10.
Fursov N, Cong M, Federici M, Platchek M, Haytko P, Tacke R, et al.
Assay Drug Dev Technol
. 2005 Mar;
3(1):7-15.
PMID: 15798391
In this article we describe the use of division-arrested cells for cell-based assays designed for high-throughput screening. Cells are the most critical and variable reagent for cell-based high-throughput screening. The...